Display Settings:

Format

Send to:

Choose Destination
    Exp Mol Med. 2011 Feb 28;43(2):63-70.

    Therapeutic effects of recombinant Salmonella typhimurium harboring CCL22 miRNA on atopic dermatitis-like skin in mice.

    Source

    Department of Biotechnology, School of Life Sciences and Biotechnology, Korea University, Seoul, Korea.

    Abstract

    Th-2-biased immune responses are known to play a key role in the pathogenesis of atopic dermatitis. In particular, the macrophage-derived chemokine CCL22 is directly implicated in Th-2-associated skin inflammatory reactions, and its levels are significantly elevated in serum and are correlated with disease severity in atopic dermatitis. In this study, we tested the development of genetic therapeutic options to treat atopic dermatitis using bacteria expressing miRNA. We constructed a recombinant strain of Salmonella typhimurium expressing CCL22 miRNA (ST-miRCCL22) for the in vivo knockdown of CCL22. The CCL22 gene was downregulated with CCL22 miRNA in activated lymphocytes. In mice with a cutaneous disease similar to atopic dermatitis, interleukin-4 was inhibited and interferon-g was induced after treatments with ST-miRCCL22. Furthermore, CCL22 levels were suppressed in the atopic mice treated with ST-miRCCL22. These results suggest that ST-miRCCL22 may be an effective genetic agent for treating atopic dermatitis.

    PMID:
    21187702
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC3047194
    Free PMC Article

    Images from this publication.See all images (5) Free text

    Figure 2
    Figure 4
    Figure 1
    Figure 3
    Figure 5

      Supplemental Content

      Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk